AXIM - AXIM completes pre-clinical studies on SPX-1009 in suppression of melanoma cells

AXIM Biotechnologies ([[AXIM]]) has completed pre-clinical drug studies on its SPX-1009 compound, demonstrating the suppression of malignant metastatic melanoma cells.The company intends to initiate animal studies to demonstrate the ability of SPX-1009 to suppress tumor growth and metastasis in a murine model of melanoma.AXIM also highlighted that its intellectual property related to the SPX-1009 technology is the subject of numerous patent-pending applications.

For further details see:

AXIM completes pre-clinical studies on SPX-1009 in suppression of melanoma cells